

References

I-9019

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Zolgensma® (onasemnogene abeparvovec-xioi) injection, for intravenous use [package insert]. AveXis, Inc. Bannockburn, IL. 2019.
3. Hayes, Inc. Hayes Prognosis Overview. Zolgensma (Onasemnogene Abeparvovec) for Spinal Muscular Atrophy. Landsdale, PA: Hayes, Inc.; February 2019.
4. Mendell J, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med*. 2017;377:1713-1722.
5. Al-Zaidy S, Pickard A, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol*. 2019;54(2):179-185.
6. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *Journal of Child Neurology*. 2007;22:1027-1049.
7. Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. *J Neuromuscul Dis*. 2019a;6(3):307-317.
8. Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. *Pediatr Neurol*. 2019;100:3-11.
9. Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. *Adv Ther*. 2019;36(5):1164-1176.
10. Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. *Pediatr Neurol*. 2019;98:39-45.
11. Micromedex DrugDex Compendium®. 2020. Onasemnogene abeparvovec.
12. Clinical Pharmacology™ Compendium. 2020. Tampa FL: Gold Standard, Inc. Onasemnogene abeparvovec.